November 28, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January-September 2023 Read more
November 28, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari-september 2023 Read more
November 21, 2023 Regulatory InDex Pharmaceuticals discontinues cobitolimod phase III program Read more
November 21, 2023 Regulatory InDex Pharmaceuticals avbryter fas III-programmet med cobitolimod Read more
November 21, 2023 Regulatory InDex Pharmaceuticals avbryter fas III-programmet med cobitolimod Read more
August 23, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2023 Read more
August 23, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – juni 2023 Read more
August 2, 2023 Regulatory InDex Pharmaceuticals has been granted a new patent in Europe for the commercial formulation of cobitolimod Read more
August 2, 2023 Regulatory InDex Pharmaceuticals har beviljats ett nytt patent i Europa för den kommersiella formuleringen av cobitolimod Read more
May 31, 2023 Regulatory InDex Pharmaceuticals announces license agreement with Viatris Japan to develop and commercialize cobitolimod in Japan Read more
May 31, 2023 Regulatory InDex Pharmaceuticals och Viatris Japan ingår licensavtal för att utveckla och kommersialisera cobitolimod i Japan Read more
May 24, 2023 Regulatory Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 24, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2023 Read more
May 24, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – mars 2023 Read more
April 19, 2023 Regulatory Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
April 12, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2022 Read more
April 12, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör årsredovisning för 2022 Read more
February 23, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) bokslutskommuniké 2022 Read more
January 27, 2023 Regulatory InDex Pharmaceuticals updates the timeline of the phase III study CONCLUDE with cobitolimod Read more
January 27, 2023 Regulatory InDex Pharmaceuticals uppdaterar tidplanen för fas III-studien CONCLUDE med cobitolimod Read more